NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	psoriasis
Date of first enrollment	14/09/2012
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Secukinumab INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : subcutaneous injection

Outcome(s)

Primary Outcome	AE
Secondary Outcome	PASI 75, IGA

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	-Subjects who complete the full study treatment period of preceding phase III studies. -Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both
Exclude criteria	-Ongoing use of prohibited psoriasis or non-psoriasis treatments. -Other protocol-defined inclusion/exclusion criteria may apply.